SEQUENCE LISTING

<110>   BIOMIRA INC. et al.

<120>   IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OIGONUCLEOTIDES

<130>   JIANG=4A PCT

<140>   PCT/CA03/00135
<141>   2003-02-04

<150>   60/353,195
<151>   2002-02-04

<160>   12

<170>   PatentIn version 3.3

<210>   1
<211>   10
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Synthesizable sequence, corresponds to 128H described in Cheng et al.
        USP 5,646,126

<400>   1
cacacgtgtg   10

<210>   2
<211>   25
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   Synthesized peptide shown in Fig. 17 BP1-148

<400>   2

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg
1   5   10   15

Pro Ala Pro Gly Ser Thr Ala Pro Pro
            20   25

<210>   3
<211>   20
<212>   DNA
<213>   Artificial Sequence

<220>
<223>   Synthesizable activating sequence, shown in Fig. 1

<400>   3

ggtgcatcga tgcagggggg   20

<210>   4
<211>   10
<212>   PRT
<213>   Leishmani major

<400>   4

Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala
1   5   10

<210>   5
<211>   25
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   MUC1 repeat consensus sequence

<400>   5

Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala Gln Thr Ala His Gly Val
1   5   10   15

Thr Ser Ala Pro Asp Glu Thr Ser Arg
            20   25

<210>   6
<211>   12
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   MUC1 fragment

<400>   6

Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr
1   5   10

<210>   7
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   MUC1 fragment

<400>   7

Thr Leu Ala Pro Ala Thr Glu Pro Ala
1   5

```
<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MUC1 fragment

<400>  8

Ala Leu Gly Ser Thr Ala Pro Pro Val
1               5


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MUC1 fragment

<400>  9

Phe Leu Ser Phe His Ile Ser Asn Leu
1               5


<210>  10
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  MUC1 repeat

<400>  10

Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
1               5                   10                  15


Pro Pro Ala His
            20


<210>  11
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthesized peptide shown in Fig. 17 as intermediate


<220>
```

```
<221>  misc_feature
<222>  (27)..(27)
<223>  Lys is modified by a palmitoyl group

<400>  11

Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Pro Asp Thr
1               5               10              15


Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Lys Gly
            20              25


<210>  12
<211>  12
<212>  PRT
<213>  Plasmodium falciparum

<400>  12

Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro
1               5               10
```